You just read:

Menlo Therapeutics Announces Successful Pruritus Reduction Results from Phase 2 Serlopitant Trial (TCP-102) in 127 Subjects With Prurigo Nodularis

News provided by

Menlo Therapeutics Inc.

Mar 08, 2017, 13:00 ET